Grant of Share Options

Oxford Pharmascience Group plc

 ("Oxford Pharmascience" or "the Company")

Grant of Share Options

Further to the RNS releases of 5 March 2014 and 6 March 2014 to notify shareholders that the Company has strengthened the executive and non-executive team, the Company now believes it has the personnel in place to execute its strategy. In order to incentivise the team to deliver these objectives, and to align their interests with those of shareholders, the Company today announces that it has, pursuant to the rules of the Company's Share Option Plan 2010, granted options to certain directors to subscribe for up to 74,500,000 ordinary shares of 0.1p each ("Ordinary Shares") at an exercise price of £0.0415 per ordinary share (the "Options") as follows:

The new Options have been granted under the Company's EMI share option plan 2010 and Unapproved share option plan 2010. Further details of the Options granted are as follows:

*based on the middle-market closing price (as derived from the AIM Appendix of the Daily Official List) of Ordinary Shares for a consecutive period of 10 days.

Following the grant of the Options the total number of ordinary shares subject to options and which could, in the future, be issued is 86,625,000. This represents 8.68% of the current issued share capital of the Company which comprises 997,536,619 Ordinary Shares.

David Norwood, Chairman of Oxford Pharmascience commented:

"These share incentives tie remuneration for the directors' performance to these stretching share price targets and should help retain and motivate key employees to drive the Company forward. A significant majority of the share options granted will only vest if the Company's share price achieves significant growth - 17% if the share price reaches 20 pence and a further 67% if the share price reaches 50 pence. These targets are both highly motivational for the directors and would represent substantial gains for shareholders against our current share price (an increase of 4.67 times and 11.68 times respectively on yesterday's closing share price).

I am delighted that we have agreed this remuneration package with the reshaped Board. Marcelo Bravo (CEO) is opting for a remuneration package at risk based on share price appreciation and has agreed to a below average salary for an AIM Company CEO without the provision for cash bonuses. This highlights Marcelo's belief in the Company and its future potential."

For further information:

Oxford Pharmascience Group Plc

Marcelo Bravo, Chief Executive +44 20 7554 5875

N+1 Singer (Nominated Adviser & Broker)

Aubrey Powell/Jen Boorer +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers, but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. 

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines, the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.